Enrolling Studies: Chlamydia

Chlamydia is a common genital infection caused by the bacteria of the Chlamydia and Chlamydophila genera.

Chlamydia is known for its resistance to various adverse factors. These bacteria are able to transform into a protective form and hide from the immune system for a long time. Also, the protective form of the bacteria helps to survive other negative effects, such as hypothermia or antibiotic therapy. When bacteria become inactive, symptoms of the infectious disease diminish. At this point, many patients stop treatment provoking a chronic course of the disease.

Chlamydia trachomatis can only reproduce in host cells. The vital activity of this microorganism is completely dependent on the energy resources of the affected cell. Therefore, chlamydia are called obligate parasites. Outside the cells, bacteria exist in the form of elementary bodies, proliferating like spores. The rigid cell wall of elementary bodies helps the parasite to hide from aggressive external factors.

The "cunning" of the chlamydial infection lies in the fact that very often it passes in an asymptomatic form. According to the CDC, about 40% of chlamydia patients do not seek medical help and are unaware of the disease. At the same time, without treatment, chlamydia causes serious complications, including female and male infertility, miscarriage and intrauterine infection of the fetus.

In our Visionaries clinic, a clinical study is being conducted on the impact of Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (EVOGUARD).

This study will evaluate whether EVO100 vaginal gel prevents the sexual transmission of CT and GC infection

In this phase 3 double-blind placebo-controlled, efficacy study, women who have had a urogenital chlamydia or gonorrhea infection at any time over the 16 weeks preceding the enrollment Visit with one or more risk factors, or found to be positive for either infection at Screening Visit with one or more risk factors will be enrolled. After a screening period of up to 35 days, women will be randomized to receive either EVO100 vaginal gel or placebo. Each woman will participate in the study until she has completed 16 weeks of study medication or observation or tests positive for CT or GC infection.

Study Design

Study Type — Interventional (Clinical Trial).
Estimated Enrollment — 1730 participants.
Allocation — Randomized.
Actual Study Start Date — October 15, 2020.
Estimated Primary Completion Date — April 22, 2022.
Estimated Study Completion Date — June 30, 2022.

Eligibility Criteria

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies

Ages Eligible for Study — 18 Years and older (Adult, Older Adult).
Sexes Eligible for Study — Female.
Gender Based Eligibility — Yes.
Gender Eligibility Description — Females Only.
Accepts Healthy Volunteers — Yes.

Recruitment Status — Recruiting

Inclusion Criteria

Urogenital CT and/or GC infection (documented in a retrievable medical record) within the 16 weeks prior to enrollment and one or more of the additional risk factors included below.

18 to 24 years of age at the screening visit.
New sex partner within the past 12 weeks (84 days).
More than one current sex partner.
Knowledge that current sex partner has multiple partners.
Partner with known sexually transmitted infection (STI).
Inconsistent condom use among persons who are not in a mutually monogamous relationship.

After three unsuccessful documented attempts to obtain medical records, the subject has a self-reported history of infection less than 17 weeks prior to enrollment AND two or more of the following additional risk factors.

18 to 24 years of age at the screening visit.
New sex partner within the past 12 weeks (84 days).
More than one current sex partner.
Knowledge that current sex partner has multiple partners.
Partner with known STI.
Inconsistent condom use among persons who are not in a mutually monogamous relationship.
Ability to understand the consent process and procedures. For minors, the ability to obtain consent from parents/legal guardian and assent by minor subjects as applicable according to local regulations.
Agree to be available for all study visits including Visit 5 and follow-up Visit 6 and comply with follow-up on staff appointment reminders.
Negative pregnancy test.
Negative CT and GC nucleic acid amplification test (NAAT) at screening or positive CT or GC NAAT and receives standard of care (SOC according to CDC or World Health Organization [WHO] guidelines) treatment prior to enrollment with subsequent negative CT and GC NAAT testing at enrollment visit.
Agree to use a woman-controlled method of contraception that is not directly delivered to the vaginal mucosa (with the exception of a vaginal ring) throughout the duration of the study, such as oral contraceptives, birth control implants, intrauterine devices (IUDs), or tubal ligation. Condom use only is not an acceptable form of contraception for this study
Able and willing to comply with all study procedures, including the use of eDiaries and reporting of all Adverse Events and concomitant medications.
Reports vaginal sexual intercourse with a male partner at least three times per month in the previous month and anticipates vaginal sexual intercourse regularly for the duration of the study.
Agree to abstain from douching or any form of vaginal suppository use (other than investigational product) during course of study.

Exclusion Criteria

In the opinion of the Investigator, has a history of substance or alcohol abuse in the last 12 months or, has issues, conditions, or concerns that may compromise the safety of the subject, impact the subject's compliance with the protocol requirements, or confound the reliability of the data acquired.
Women who have undergone a total hysterectomy (had uterus and cervix removed). However, women with subtotal hysterectomy with an intact cervix may be enrolled
Has a history or expectation of noncompliance with medications or intervention protocol.
Has engaged in sexual vaginal intercourse or douching, or used of any form of vaginal suppository or intravaginal device (with the exception of contraceptive vaginal ring or tampons) for 24 hours prior to enrollment (may be enrolled at a later date if all other criteria are met).
Menstruating at enrollment (may be enrolled at a later date if all other criteria are met).
Is currently being treated, or has been treated, for a period of 21 days prior to enrollment, with any prohibited antibiotics. The prohibited antibiotics include azithromycin, erythromycin, doxycycline, levofloxacin, ofloxacin, ceftriaxone, and cefixime.
In the opinion of the Investigator, has signs/symptoms that indicate persistence of CT or GC infection diagnosed at screening, new interval infection, and/or a failure to comply with or complete the prescribed treatment regimen following a positive screening NAAT.

Data taken from the site clinicaltrials.gov